You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
樂普生物-B(02157.HK):MRG003臨牀試驗數據入選2025年ASCO年會的LBA口頭彙報
格隆匯 03-27 17:51

格隆匯3月27日丨樂普生物-B(02157.HK)發佈公吿,公司自主研發的候選藥物MRG003(一種表皮生長因子受體(“EGFR”)靶向抗體藥物偶聯物(“ADC”)候選藥物,用於治療複發性或轉移性鼻咽癌(“R/M NPC”))的關鍵註冊性IIb期研究結果,入選2025年美國臨牀腫瘤學會(“ASCO”)年會“重磅研究摘要(LBA)”,並將於會上作口頭報吿。

根據披露,MRG003是一種由EGFR靶向單克隆抗體與強效的微管抑制有效載荷一甲基澳瑞他汀E分子通過纈氨酸-瓜氨酸鏈接體偶聯而成的ADC。其以高親和力特異性地結合腫瘤細胞表面的EGFR,通過內吞及溶酶體蛋白酶裂解後釋放強效的有效載荷,從而導致腫瘤細胞死亡。EGFR高表達於結直腸癌、肺癌、頭頸癌等多種惡性實體瘤中,89%的晚期NPC存在EGFR表達。因此,EGFR是癌症治療的重要靶點。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account